Anthem FY26 Revenue Up 15% to ₹21,243 Mn

Anthem Biosciences reported FY26 consolidated revenue of ₹21,243 Mn, a 15.2% YoY growth, with CRDMO business leading at ₹17,727 Mn.
EBITDA for FY26 stood at ₹9,896 Mn with 43.4% margins, while PAT grew 31.1% YoY to ₹5,918 Mn with 26.0% margins.
Q4FY26 performance was strong with revenue up 26.4% YoY to ₹6,109 Mn and PAT surging 129.8% YoY to ₹1,898 Mn.
The company maintained a robust net cash position of ₹13,743 Mn as of March 31, 2026, supporting future growth initiatives.